Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 12/20 | 0.36 |
| ▸ | MMP3 | P08254 | 5/20 | 0.36 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.36 |
| ▸ | MMP12 | P39900 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
| ▸ | MMP9 | P14780 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7047981 | 0.92 | DGAT1 (0.34) | MMP2MMP3DGAT1MMP1MMP9 | |
| SCHEMBL7765078 | 0.73 | MMP2 (0.44) | MMP2MMP3MMP12MMP1MMP9 | |
| SCHEMBL7758482 | 0.67 | MMP2 (0.62) | MMP2MMP3 | |
| SCHEMBL7758573 | 0.67 | MMP2 (0.71) | MMP2MMP3 | |
| SCHEMBL7758571 | 0.59 | MMP2 (0.57) | MMP2MMP3 | |
| SCHEMBL7758477 | 0.59 | MMP2 (0.52) | MMP2MMP3 | |
| SCHEMBL7758582 | 0.59 | MMP2 (0.57) | MMP2MMP3 | |
| SCHEMBL7758485 | 0.59 | MMP2 (0.52) | MMP2MMP3 | |
| SCHEMBL7761563 | 0.59 | MMP2 (0.60) | MMP2MMP3 | |
| SCHEMBL7761567 | 0.59 | MMP2 (0.60) | MMP2MMP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | CASTELHANO ARLINDO LUCAS (US) | 2003-11-13 | — | — | US | disclosed |
| US-6579890-B1 | Matrix metalloprotease inhibitors | SYNTEX (U.S.A.) INC. | 2003-06-17 | — | — | US | disclosed |
| US-6037472-A | FOR TREATING DISEASE-STATES CHARACTERIZED BY EXCESSIVE ACTIVITY OF MATRIX METALLOPROTEASES SUCH AS RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, PERIODONTAL DISEASE, ABERRANT ANGIOGENESIS, TUMOR INVASION AND METASTASIS | SYNTEX (U.S.A.) INC. (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0793643-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016027-A1 | MATRIX METALLOPROTEASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212067-A1 | Matrix metalloprotease inhibitors | MMP7, MMP1, MMP3 | MMP2 8/4885MMP3 3/4885DGAT1 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.